Literature DB >> 24867988

Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.

Reem Almaghrabi1, Cornelius J Clancy2, Yohei Doi1, Binghua Hao3, Liang Chen4, Ryan K Shields3, Ellen G Press1, Nicole M Iovine5, Bethany M Townsend1, Marilyn M Wagener6, Barry Kreiswirth4, M Hong Nguyen3.   

Abstract

We measured in vitro activity of plazomicin, a next-generation aminoglycoside, and other aminoglycosides against 50 carbapenem-resistant Klebsiella pneumoniae strains from two centers and correlated the results with the presence of various aminoglycoside-modifying enzymes (AMEs). Ninety-four percent of strains were sequence type 258 (ST258) clones, which exhibited 5 ompK36 genotypes; 80% and 10% of strains produced Klebsiella pneumoniae carbapenemase 2 (KPC-2) and KPC-3, respectively. Ninety-eight percent of strains possessed AMEs, including AAC(6')-Ib (98%), APH(3')-Ia (56%), AAC(3)-IV (38%), and ANT(2")-Ia (2%). Gentamicin, tobramycin, and amikacin nonsusceptibility rates were 40, 98, and 16%, respectively. Plazomicin MICs ranged from 0.25 to 1 μg/ml. Tobramycin and plazomicin MICs correlated with gentamicin MICs (r = 0.75 and 0.57, respectively). Plazomicin exerted bactericidal activity against 17% (1× MIC) and 94% (4× MIC) of strains. All strains with AAC(6')-Ib were tobramycin-resistant; 16% were nonsusceptible to amikacin. AAC(6')-Ib combined with another AME was associated with higher gentamicin, tobramycin, and plazomicin MICs than AAC(6')-Ib alone (P = 0.01, 0.0008, and 0.046, respectively). The presence of AAC(3)-IV in a strain was also associated with higher gentamicin, tobramycin, and plazomicin MICs (P = 0.0006, P < 0.0001, and P = 0.01, respectively). The combination of AAC(6')-Ib and another AME, the presence of AAC(3)-IV, and the presence of APH(3')-Ia were each associated with gentamicin resistance (P = 0.0002, 0.003, and 0.01, respectively). In conclusion, carbapenem-resistant K. pneumoniae strains (including ST258 clones) exhibit highly diverse antimicrobial resistance genotypes and phenotypes. Plazomicin may offer a treatment option against strains resistant to other aminoglycosides. The development of molecular assays that predict antimicrobial responses among carbapenem-resistant K. pneumoniae strains should be a research priority.
Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24867988      PMCID: PMC4135979          DOI: 10.1128/AAC.00099-14

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme.

Authors:  Chi Hye Park; Ari Robicsek; George A Jacoby; Daniel Sahm; David C Hooper
Journal:  Antimicrob Agents Chemother       Date:  2006-09-05       Impact factor: 5.191

2.  Complete nucleotide sequence of pK245, a 98-kilobase plasmid conferring quinolone resistance and extended-spectrum-beta-lactamase activity in a clinical Klebsiella pneumoniae isolate.

Authors:  Ying-Tsong Chen; Hung-Yu Shu; Ling-Hui Li; Tsai-Lien Liao; Keh-Ming Wu; Yih-Ru Shiau; Jing-Jou Yan; Ih-Jen Su; Shih-Feng Tsai; Tsai-Ling Lauderdale
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

3.  Gentamicin susceptibility in Escherichia coli related to the genetic background: problems with breakpoints.

Authors:  L Jakobsen; D Sandvang; V F Jensen; A M Seyfarth; N Frimodt-Møller; A M Hammerum
Journal:  Clin Microbiol Infect       Date:  2007-05-14       Impact factor: 8.067

4.  First detection of plasmid-mediated, quinolone resistance determinants qnrA, qnrB, qnrS and aac(6')-Ib-cr in extended-spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae in Budapest, Hungary.

Authors:  Dóra Szabó; Béla Kocsis; László Rókusz; Júlia Szentandrássy; Katalin Katona; Katalin Kristóf; Károly Nagy
Journal:  J Antimicrob Chemother       Date:  2008-05-13       Impact factor: 5.790

5.  Carbapenem-resistant Klebsiella pneumoniae exhibit variability in capsular polysaccharide and capsule associated virulence traits.

Authors:  Elizabeth Diago-Navarro; Liang Chen; Virginie Passet; Seth Burack; Amaia Ulacia-Hernando; Rosy Priya Kodiyanplakkal; Michael H Levi; Sylvain Brisse; Barry N Kreiswirth; Bettina C Fries
Journal:  J Infect Dis       Date:  2014-03-14       Impact factor: 5.226

6.  The most frequently occurring aminoglycoside resistance mechanisms--combined results of surveys in eight regions of the world. The Aminoglycoside Resistance Study Groups.

Authors: 
Journal:  J Chemother       Date:  1995-06       Impact factor: 1.714

7.  PCR detection of aminoglycoside resistance genes: a rapid molecular typing method for Acinetobacter baumannii.

Authors:  I Noppe-Leclercq; F Wallet; S Haentjens; R Courcol; M Simonet
Journal:  Res Microbiol       Date:  1999-06       Impact factor: 3.992

8.  Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center.

Authors:  Kristine M Hujer; Andrea M Hujer; Edward A Hulten; Saralee Bajaksouzian; Jennifer M Adams; Curtis J Donskey; David J Ecker; Christian Massire; Mark W Eshoo; Rangarajan Sampath; Jodi M Thomson; Philip N Rather; David W Craft; Joel T Fishbain; Allesa J Ewell; Michael R Jacobs; David L Paterson; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2006-09-25       Impact factor: 5.191

Review 9.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

10.  The KQ element, a complex genetic region conferring transferable resistance to carbapenems, aminoglycosides, and fluoroquinolones in Klebsiella pneumoniae.

Authors:  Louis B Rice; Lenore L Carias; Rebecca A Hutton; Susan D Rudin; Andrea Endimiani; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

View more
  44 in total

Review 1.  [New antibacterial agents on the market and in the pipeline].

Authors:  W V Kern
Journal:  Internist (Berl)       Date:  2015-11       Impact factor: 0.743

2.  Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.

Authors:  Ghady Haidar; Cornelius J Clancy; Liang Chen; Palash Samanta; Ryan K Shields; Barry N Kreiswirth; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

Review 3.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

Review 4.  Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Children.

Authors:  Kathleen Chiotos; Molly Hayes; Jeffrey S Gerber; Pranita D Tamma
Journal:  J Pediatric Infect Dis Soc       Date:  2020-02-28       Impact factor: 3.164

5.  Global Dissemination of blaKPC into Bacterial Species beyond Klebsiella pneumoniae and In Vitro Susceptibility to Ceftazidime-Avibactam and Aztreonam-Avibactam.

Authors:  Krystyna M Kazmierczak; Douglas J Biedenbach; Meredith Hackel; Sharon Rabine; Boudewijn L M de Jonge; Samuel K Bouchillon; Daniel F Sahm; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2016-07-22       Impact factor: 5.191

Review 6.  What we may expect from novel antibacterial agents in the pipeline with respect to resistance and pharmacodynamic principles.

Authors:  Karen Bush; Malcolm G P Page
Journal:  J Pharmacokinet Pharmacodyn       Date:  2017-02-04       Impact factor: 2.745

7.  Aminoglycosides for Treatment of Bacteremia Due to Carbapenem-Resistant Klebsiella pneumoniae.

Authors:  Ryan K Shields; Cornelius J Clancy; Ellen G Press; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2016-04-22       Impact factor: 5.191

8.  Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure.

Authors:  Deanna J Buehrle; Ryan K Shields; Lloyd G Clarke; Brian A Potoski; Cornelius J Clancy; M Hong Nguyen
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

Review 9.  Aminoglycosides: An Overview.

Authors:  Kevin M Krause; Alisa W Serio; Timothy R Kane; Lynn E Connolly
Journal:  Cold Spring Harb Perspect Med       Date:  2016-06-01       Impact factor: 6.915

Review 10.  Carbapenemase-producing Enterobacteriaceae.

Authors:  Yohei Doi; David L Paterson
Journal:  Semin Respir Crit Care Med       Date:  2015-02-02       Impact factor: 3.119

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.